Ascendiant raised the firm’s price target on NRx Pharmaceuticals (NRXP) to $48 from $47 and keeps a Buy rating on the shares following the Q3 report in November. The firm sees “major opportunities” for NRX-100 and NRX-101, which should both have FDA action dates in 2026. The firm sees these news events driving NRx shares in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- NRx Pharmaceuticals Completes Debt Repayment, Ends 2025 Debt-Free
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—12/23/25
- Vanguard Total Stock Market ETF (VTI) Daily Update—12/22/25
- NRx Pharmaceuticals announces elimination of all balance sheet debt
- Vanguard Total Stock Market ETF (VTI) Daily Update—12/17/25